Earlier this week, the U.S. Food and Drug Administration approved the molecularly targeted therapeutic ribociclib (Kisqali) for use in combination with any aromatase inhibitor for initial treatment of postmenopausal women with a hormone receptor (HR)–positive, HER2-negative, advanced breast cancer.Read More
The fact that there are differences in screening mammography recommendations highlights the need for additional research into the benefits and potential risks of mammography screening.Read More
Results from the phase III clinical trial BELLE-3, presented at the San Antonio Breast Cancer Symposium on Dec. 8, showed that the phosphoinositide 3-kinase (PI3K) inhibitor buparlisib was effective in …Read More
Data presented at the San Antonio Breast Cancer Symposium showed that five additional years of the aromatase inhibitor (AI) therapy letrozole (Femara) following an initial five years of AI-based adjuvant hormone therapy did not significantly improve survival outcomes in postmenopausal women with early-stage HR-positive breast cancer. The additional five years did improve some outcomes related to recurrence.Read More
A study presented Thursday, Dec. 8, at the San Antonio Breast Cancer Symposium found that women who received breast implants had more than double the odds of developing complications if they had received radiotherapy.Read More
Genomic analysis of estrogen receptor (ER)-positive metastatic breast cancer samples that had become resistant to therapies revealed multiple alterations that were not present in the primary tumor samples.Read More
SABCS is a comprehensive scientific meeting that provides the latest information on prevention, diagnosis, and treatment of breast cancer and premalignant breast disease to various stakeholders in the field.Read More
Sasha Stanton, MD, PhD, is a breast cancer physician-scientist dedicated to developing a DCIS vaccine.Read More
This month is Breast Cancer Awareness Month, a type of cancer against which we have made much progress. However, a recent report from the Centers for Disease Control and Prevention (CDC) highlights that the progress we are making has not been uniform for all segments of the population.Read More
As the temperature soared this summer, the laps around the park became harder to endure.
When her skin chafed from radiation, her doctor told her to take it easy.
Still, Tanya Hall …